Acute myeloid leukemia research hub
50 indexed studies · 34 currently recruiting
- recruitingPhase II/III
Optimising therapy in FLT3-mutated acute myeloid leukaemia
This clinical trial looks at the best chemotherapy combinations for people newly diagnosed with acute myeloid leukaemia (AML) who have a specific gene change called FLT3. It compares current standard treatment with two new drug mixtures to see which clears the cancer best and prevents it from returning.
United Kingdom · England · Northern Ireland - recruitingPhase I and Phase II (Integrated)- Other
A SAFETY RUN-IN AND PHASE 2, OPEN-LABEL, MULTICENTRE, STUDY INVESTIGATING SAFETY, TOLERABILITY AND EFFECTIVENESS OF VENETOCLAX ADD IN COMBINATION AT FLUDARABINE, CYRATABINE AND IDARUBICINE IN INDUCTION THERAPY OF NEW ONSET NON-M3 ACUTE MYELOID LEUKEMIA. V-FIRST - AML1718
This study looks at a new treatment combination for adults newly diagnosed with acute myeloid leukaemia (AML). It tests whether adding a targeted medicine called venetoclax to standard chemotherapy is safe, well-tolerated, and better at clearing leukaemia cells from the bone marrow and blood.
Italy - authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements
This clinical trial is testing a new experimental medicine called CHM-029 for adults with acute myeloid leukaemia (AML). Doctors want to find out if the drug is safe, what the best dose is, and whether it works well alone or when given alongside standard leukaemia treatments.
France · Germany · Spain - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy, Incorporating Extension Period - Continued Access for Venetoclax. (VIALE-A)
This study looks at a new treatment called venetoclax combined with an existing medicine called azacitidine for people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It aims to see if this combination works better than azacitidine alone for patients who can't have standard strong chemotherapy.
Finland · Czechia · Hungary - recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
This study looks at a new combination treatment for acute myeloid leukaemia (AML) in people who can't have strong chemotherapy. It compares a drug called Venetoclax plus a low-dose chemotherapy called Cytarabine, to just low-dose Cytarabine on its own, to see which is more effective.
France - recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
This study is looking at a new combination treatment for acute myeloid leukaemia (AML) in people who can't have strong chemotherapy. It combines two drugs, cusatuzumab and azacitidine, to see how well they help improve the patient's condition.
Spain - recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML).
This study is looking at a new combination treatment for acute myeloid leukemia (AML), a type of blood cancer. It combines a new drug, Liposomal Annamycin, with a standard treatment, cytarabine. Researchers want to see if this new combination is safe and effective.
Poland · Italy - recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in adults who can't have strong chemotherapy. It compares a drug combination of three medicines (pevonedistat, venetoclax, and azacitidine) against a two-drug combination (venetoclax and azacitidine) to see which works best.
Italy · Poland - recruitingPhase I and Phase II (Integrated)- Other
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refractory Acute Myeloid Leukemia and in Combination with 5-Azacytidine and Venetoclax for Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Negative for NPM1 and IDH 1/2 Mutations Who Are Ineligible for Intensive Chemotherapy (AARON)
This study looks at new drug combinations for acute myeloid leukaemia (AML). It aims to find the safest dose and see how well these combinations work in people whose AML has come back or not responded to treatment, and in newly diagnosed patients who can't have strong chemotherapy.
Germany - recruitingTherapeutic exploratory (Phase II)
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse (PEMAZA)
This study looks at a new way to treat acute myeloid leukaemia (AML) in adults. It's for people whose AML might be coming back. We're testing a combination of two medicines, pembrolizumab and azacitidine, to see if it can keep the cancer away for longer.
Germany - authorisedTherapeutic exploratory (Phase II)
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
This study looks at a new drug, Tambiciclib, given with standard leukaemia treatments (Venetoclax and Azacitidine). It's for adults with acute myeloid leukaemia (AML) whose first two cycles of standard treatment didn't work well enough. Researchers want to see if adding Tambiciclib improves how many patients respond to treatment.
Italy · Spain - recruitingPhase III
A Phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation
This study tests a new medicine called mocravimod for adults with acute myeloid leukaemia having a donor stem cell transplant. Researchers want to see if mocravimod can stop the cancer from returning and protect healthy organs from donor cell attacks, a common and serious complication called graft-versus-host disease.
United Kingdom · Argentina · Brazil - recruitingTherapeutic exploratory (Phase II)
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)
This study looks at a new way to treat acute myeloid leukaemia (AML) in adults who can't have standard treatment. It combines two existing medicines, Venclyxto and Vidaza, to see how well they work together and if they can help patients get better.
Germany - recruitingPhase III
A study of bleximenib, venetoclax and azacitidine for treatment of participants with newly diagnosed acute myeloid leukemia (cAMeLot-2)
This study looks at a new drug, bleximenib, combined with existing treatments (Venetoclax and Azacitidine) for newly diagnosed acute myeloid leukaemia (AML). It aims to see if this combination works better for patients not able to have strong chemotherapy, specifically those with certain genetic changes in their AML.
United Kingdom · England · Scotland - recruitingHuman Pharmacology (Phase I)- First administration to humans
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
This study is looking into a new treatment called KITE-222 for adults with a type of blood cancer called Acute Myeloid Leukemia (AML) that has come back or hasn't responded to previous treatments. It's an early-stage study to see how safe the treatment is.
France · Germany - recruitingPHASE1, PHASE2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
This study is looking at a new medicine called revumenib for different types of leukaemia that have come back or not responded to treatment. It aims to find the right dose and see how well it works and if it's safe for people with certain genetic changes in their leukaemia.
United States · Australia · Canada - active not recruitingPHASE2
Dexamethasone Added to Intensive Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML)
This study is testing if adding a drug called dexamethasone to standard chemotherapy can help older patients with a type of blood cancer called Acute Myeloid Leukaemia (AML). Researchers want to see if this combination improves treatment success.
France - recruitingPHASE3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
This study looks at a new drug called venetoclax for children, teenagers, and young adults with acute myeloid leukaemia (AML) that has come back. It aims to see if adding venetoclax to standard chemotherapy can help improve their chances of survival.
United States · Australia · Austria - active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
United States · Australia · Austria - recruitingPHASE3
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
This study looks at new ways to treat acute myeloid leukaemia (AML) that has come back or hasn't responded to earlier treatment. It compares stronger treatments with gentler ones to see which works best for patients in their first or second relapse.
Czechia · Germany · Italy - active not recruiting
MIF Involvement in AML
This study looks into how a protein called MIF might be involved in adult Acute Myeloid Leukemia (AML). Researchers are examining samples from patients to understand MIF's role and how it could help predict treatment outcomes or lead to new ways to fight the disease.
France - active not recruitingPHASE1, PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
This study is testing a new drug, IMGN632, for adults with a type of blood cancer called Acute Myeloid Leukemia (AML). It's looking at whether IMGN632 is safe and effective when given alone or with other common AML treatments.
United States · France · Germany - active not recruitingPHASE3
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
This study is looking at a new combination of medicines (CPX-351) compared to standard treatment for adults newly diagnosed with a type of blood cancer called Acute Myeloid Leukemia (AML). We want to see if the new combination helps people live longer.
Austria · Germany - active not recruiting
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
This study looks at how well a medication called venetoclax works for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for patients who can't have strong chemotherapy. The study will follow about 200 people in Canada to see how their condition changes with venetoclax.
Canada - recruiting
Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy
This study looks at gut problems in people with acute myeloid leukaemia (AML) undergoing strong treatment. We want to find out how common a serious gut infection called neutropenic enterocolitis is, and other gut issues, to diagnose them earlier and improve care for patients.
France - recruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
United States · France · Spain - active not recruitingPHASE3
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
This study looks at a new drug, galinpepimut-S, for people with a type of blood cancer called Acute Myeloid Leukaemia (AML) who are in remission. It compares the new drug to standard treatments to see if it helps people live longer.
United States · France · Germany - recruitingPHASE1, PHASE2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.
Belgium · France · Italy - recruitingPHASE1, PHASE2
Study to Evaluate the Safety and Tolerability of EP0042
This study is looking at a new treatment called EP0042 for advanced blood cancers like acute myeloid leukaemia (AML). It aims to find a safe and effective dose of EP0042, sometimes combined with other medicines, for patients whose cancer treatments haven't worked or have stopped working.
Australia · Netherlands · United Kingdom - enrolling by invitationPHASE2
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
This study is for people who are already taking a medicine called ASTX727 for certain blood cancers (like acute myeloid leukaemia, chronic myelomonocytic leukaemia, or myelodysplastic syndromes) in other studies, and it's helping them. It’s a way to keep taking the medicine and gather long-term safety information.
United States · Armenia · Austria - recruitingPHASE2
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
This study compares a new treatment, CPX-351, with standard chemotherapy for people aged 50 and over newly diagnosed with acute myeloid leukaemia (AML) that has certain genetic markers. It aims to see if CPX-351 is more effective.
France - recruiting
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
This study looks at new ways to understand why leukaemia might come back after a stem cell transplant. It focuses on specific changes in the leukaemia cells, hoping to find better treatments, especially for people whose leukaemia has returned after this type of transplant.
Germany - recruiting
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
This study aims to understand why some children and young people with acute myeloid leukaemia (AML) don't get better or have their cancer come back. Researchers will collect blood and bone marrow samples to look closely at the cancer cells and test new ways to treat them, hoping to find better ways to fight this disease.
France - recruitingPHASE2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This study helps doctors find the best treatments for people with certain blood cancers like leukaemia. It uses special tests on blood and bone marrow to match patients with personalised treatments or standard care, aiming to improve how cancer treatments are chosen.
United States · Canada · Puerto Rico - not yet recruitingNA
Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia
This study looks at how hypnosis and virtual reality might help people with acute myeloid leukaemia (AML) feel less anxious during their first chemotherapy. We're comparing standard care with hypnosis, standard care with virtual reality, and standard care alone to see the effects.
France - recruitingNA
Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia
This study looks at a new treatment called 'micro-transplantation' for older people with a type of blood cancer called acute myeloid leukaemia (AML). It's for those who can't have standard transplants. Researchers want to see how safe and effective this new approach is.
France - recruitingPHASE2
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
This study looks at whether a medicine called tranexamic acid can help stop bleeding in people with certain blood cancers like MDS and AML. Some patients will get the medicine, others a dummy pill. We want to see if it safely reduces bleeding problems.
Canada - recruitingPHASE2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This study looks at new ways to treat a serious type of blood cancer called AML in people aged 18-59. It compares standard treatment with newer drug combinations to see if they work better at shrinking the cancer.
United States · Canada · Puerto Rico - recruitingPHASE1, PHASE2
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
This study looks at blood and bone marrow from children and young people with leukaemia that's come back or is hard to treat. It helps doctors understand the leukaemia better, which could lead to improved treatments and new ways to diagnose and care for young patients.
United States · Australia · Canada - recruitingPHASE1
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This study is looking at a new drug, Pivekimab Sunirine, for children and young people with a type of blood cancer called acute myeloid leukaemia (AML). It aims to see how safe the drug is and how it moves through the body, especially when other treatments haven't worked.
United States · Australia · France - active not recruitingPHASE2
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
This study looks at giving an extra treatment called donor lymphocyte infusion (DLI) early after a stem cell transplant for people with acute myeloid leukaemia (AML). The aim is to see if this helps stop the leukaemia from coming back.
France - active not recruitingPHASE4
CINC424A2X01B Rollover Protocol
This study is for patients already taking ruxolitinib, or ruxolitinib with panobinostat, in a previous trial, and who are still benefiting. It lets them continue their treatment and helps researchers learn more about the long-term safety of these medications.
Australia · Belgium · Bulgaria - recruitingPHASE3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
This study is for adults aged 18-75 recently diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML) or certain types of Myelodysplastic Syndrome. It tests a new drug, venetoclax, alongside standard chemotherapy, to see if this combination works better than chemotherapy alone.
Austria · Belgium · Estonia - active not recruitingPHASE1, PHASE2
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
This study is testing a new drug called ziftomenib for people with a type of blood cancer called acute myeloid leukaemia (AML) that has come back or not responded to previous treatments. It's the first time this drug is being used in people.
United States · Belgium · Canada - active not recruitingPHASE2
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
This study looks at a new drug, imetelstat, for people with specific types of blood cancer (high-risk MDS or AML) whose previous treatments haven't worked well. It aims to see how effective and safe imetelstat is in improving blood conditions.
Australia · France · Germany - active not recruitingPHASE1
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
This study looks at a new way to treat acute myeloid leukaemia (AML) in adults. It's a first-stage trial to see if a modified treatment, using your own AML cells to produce a protein called IL-12, is safe and helpful, especially if a bone marrow transplant isn't an option.
Canada - recruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Austria · Belgium · Denmark - active not recruitingPHASE1, PHASE2
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This study looks at a new drug, bexmarilimab, alongside standard treatments for certain blood cancers like leukaemia and MDS. We want to find a safe dose and see how well it works to help patients.
United States · Finland · United Kingdom - recruitingPHASE2, PHASE3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
This study is testing new ways to treat certain blood cancers, like some types of leukaemia and myelodysplastic syndromes. Researchers are looking at a new drug, ASTX030, sometimes with another drug called venetoclax, to see if it's safe and works better than current treatments.
United States · Canada · Czechia - authorisedTherapeutic exploratory (Phase II)
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
This study is testing a new drug called Revumenib with standard chemotherapy for children and young people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for those whose cancer has returned after treatment or hasn't responded to initial therapy.
Denmark · Italy · Czechia